This promotional website has been developed, organised and funded by Boehringer Ingelheim.
Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.
Proven efficacy vs placebo1,6
Proven efficacy vs placebo.1,6 The efficacy and safety of 5 mg linagliptin was evaluated in eight phase III randomised controlled trials. Linagliptin once daily demonstrated clinically significant improvements in glycaemic control vs placebo or comparator1
Demonstrated CV and kidney safety profile
Long-term cardiovascular and kidney safety profile of TRAJENTA® has been emonstrated in two cardiovascular outcome trials.7-12 As TRAJENTA® is primarily excreted via the bile, it is suitable for a broad range of adults with type 2 diabetes independent of renal function.1
Unique convenience of one dose, once daily1
The recommended dose of TRAJENTA® for adult patients with type 2 diabetes is 5 mg once daily, independent of renal and hepatic function, body mass index, age, ethnicity, background type 2 diabetes therapy, and disease duration1,13
UPCOMING EVENTS & CONTENT
How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?
Join our faculty as they discuss the role of clinical inertia in the suboptimal achievement of treatment targets and share practical tips for addressing this topic with your adult type 2 diabetes patients
The event starts in:
*Summary of Product Characteristics for Trajenta, sitagliptin, vildagliptin and saxagliptin are available at: https://www.medicines.org.uk (GB), https://www.emcmedicines.com/en-GB/northernireland/ (NI) and https://www.medicines.ie/ (ROI).
**Summary of Product Characteristics for alogliptin are available at: https://www.medicines.org.uk (GB) and https://www.emcmedicines.com/en-GB/northernireland/ (NI).
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
PC-GB-106627 V2 | March 2023
This website is for healthcare professionals in Great Britain, Northern Ireland and Republic of Ireland only.